QS-21 + sTn(c)-KLH

QS-21 + sTn(c)-KLH is a combination investigational cancer vaccine formulation. It consists of two main components: - **QS-21** is a purified plant-derived triterpene glycoside (saponin) adjuvant extracted from the bark of the Quillaja saponaria tree. It enhances both humoral and cell-mediated immune responses to co-administered antigens by stimulating cytotoxic T-cell proliferation and promoting antigen uptake by antigen-presenting cells[1][2][3]. - **sTn(c)-KLH** is a conjugate of the tumor-associated carbohydrate antigen *sialyl-Tn* (sTn), in its clustered form (c), covalently linked to keyhole limpet hemocyanin (KLH), which serves as an immunogenic carrier protein. The goal is to induce an immune response against cancer cells expressing the sialyl-Tn antigen, commonly found on mucins in various epithelial cancers[4]. This combination has been evaluated in early-phase clinical trials for several cancers, including breast, ovarian, and prostate cancer. The vaccine aims to provoke both IgM and IgG antibodies targeting tumor-associated carbohydrate antigens such as sialyl-Tn[4][5].

Other names

QS-21 and sTn(c)-KLHQS-21 plus sTn(c)-KLHSaponin adjuvant with sialyl-Tn-KLH conjugate